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Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder with defective structure and/or function of
motile cilia/flagella, causing chronic upper and lower respiratory tract infections, fertility problems, and disorders of
organ laterality. Diagnosing PCD requires a combined approach utilizing characteristic phenotypes and complementary
methods for detection of defects of ciliary function and ultrastructure, measurement of nasal nitric oxide and genetic
testing. Currently, biallelic mutations in 31 different genes have been linked to PCD allowing a genetic diagnosis in
approximately ~ 60% of cases. Management includes surveillance of pulmonary function, imaging, and microbiology of
upper and lower airways in addition to daily airway clearance and prompt antibiotic treatment of infections.
Early referral to specialized centers that use a multidisciplinary approach is likely to improve outcomes.
Currently, evidence-based knowledge on PCD care is missing let alone management guidelines. Research and
clinical investigators, supported by European and North American patient support groups, have joined forces
under the name of BESTCILIA, a European Commission funded consortium dedicated to improve PCD care and
knowledge. Core programs of this network include the establishment of an international PCD registry, the generation
of disease specific PCD quality of life questionnaires, and the first randomized controlled trial in PCD.Review
The term primary ciliary dyskinesia (PCD (MIM 244400))
has been used for a clinically and genetically heterogeneous
group of recessive disorders with defective ciliary motility
resulting in chronic upper and lower respiratory tract dis-
ease. Organ laterality defects occur in approximately ~50%
of cases, usually situs inversus totalis (Kartagener’s syn-
drome). In 1976, Afzelius reported that PCD is character-
ized by ultrastructural defects of cilia leading to ‘immotile’
cilia [1]. Subsequent research lead to the replacement of
the term ‘immotile cilia syndrome’ by ‘primary ciliary dys-
kinesia’ in order to emphasize that not only ciliary immoti-
lity but also abnormal ciliary motility causes PCD [2]. Even
this term seems to be inappropriate to cover all disease
variants, as demonstrated by the recent identification of a
disease entity characterized by typical, severe clinical PCD
features (without situs abnormalities) caused by defective
generation of multiple motile cilia [3,4]. This review pro-
vides a state-of-the art overview on diagnosis and man-
agement of PCD. It augments knowledge summarized* Correspondence: Claudius.Werner@ukmuenster.de
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unless otherwise stated.in recent reviews [2,5-10]. Due to the thematic overlap,
partial similarities to these reviews are inevitable.Epidemiology
The PCD prevalence is difficult to determine [11] and is
in the range of 1:4,000 to <1:50,000 [12]. Most likely, this
rather reflects differences in access to diagnostic facilities
as several complex diagnostic tests, which are not univer-
sally available, have to be combined for diagnosing PCD.
On the other hand, some degree of variability can be
explained by a higher prevalence in societies with a
high degree of consanguinity [13].Diagnosis
PCD is both under-diagnosed and diagnosed too late [12].
Therefore, clinicians should increase their level of suspi-
cion for PCD in patients with typical phenotypes (Table 1).
Diagnosing PCD requires a combined approach of com-
plementary methods (Table 2; Figure 1), all of which have
limitations [2,14]. As most institutions do not have ad-
equate resources for a thorough diagnostic evaluation,
referral to specialized centers is strongly recommended
[2,6,11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Candidates for primary ciliary dyskinesia (PCD)
testing (adapted from [5,11])
1. Individuals with situs inversus totalis or other situs abnormalities
2. Individuals with both upper and lower respiratory tract disease
a. Upper airways disease includes: chronic rhinitis/nasal discharge,
chronic sinusitis, hearing impairment due to glue ear, chronic
otitis media
b. Lower airways disease includes: chronic wet cough, atelectasis or
bronchiectasis, notably in middle lobe, lingula or lower lobes,
chronic/recurrent bronchitis/pneumonia
3. History of unexplained neonatal respiratory distress
4. Positive family history (for example, affected sibling)
5. Congenital heart defect, notably if upper/lower airways disease and
heterotaxy are present
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Up to 85% of individuals with PCD have a history of un-
explained neonatal respiratory distress [15]. Symptoms
comprise mild transient tachypnoea, atelectasis, and can
advance to respiratory failure requiring ventilatory sup-
port. Directly after birth, neonates with PCD present with
persistent rhinitis or a blocked nose leading to feeding dif-
ficulties. Chronic rhinosinusitis develops in childhood and
lasts through adulthood (Figure 2). Already during infancy,
conductive hearing loss frequently occurs due to middle
ear effusion that may progress to glue ear. Infants typically
develop daily wet cough and recurrent upper and lower
airways infections. Although a life-long symptom, patients
often do not report cough as under-recognition due to
adaptation to this ever-present symptom or cough sup-
pression due to embarrassment are common. Consolida-
tion, atelectasis, and bronchiectasis are constant findings
in adults but may be present already in infancy (Figure 2)
[15]. Typically, the middle and lingula lobes of the lung
are affected predominantly followed by the lower lobes.
Involvement of the upper lobes usually occurs at a later
disease stage [16].
In many PCD variants, ciliary dysfunction also involves
cilia of the embryonic node which are essential for estab-
lishing the left-right asymmetry of visceral organs. Dys-
function of these nodal cilia results in a randomization of
left-right body asymmetry. Hence, 40% to 50% of PCDTable 2 Methods and limitations used for confirmation of PC
Method Limitation
Nasal NO level May be decreased in oth
values may be present in
High frequency video microscopy (HVMA) Variants with subtle beatin
due to infection and inflam
Transmission electron microscopy (TEM) Approximately ~30% of P
common in some variant
Immunofluorescence microscopy (IF) No abnormality in approx
Genetics Expensive due to high nu
by genetic testing at presindividuals present with situs inversus totalis, a condition
known as Kartagener’s syndrome, and a smaller subset of
individuals (at least 6.3%) display complex situs anomalies
associated with congenital heart disease [17]. Of note,
respiratory symptoms are very common in patients with
heterotaxy and complex cardiac disease due to the heart
defect [18]. Thus, these patients have a high risk that PCD,
a chronic respiratory disease requiring specific manage-
ment, may be overlooked.
As the structure of sperm flagella is similar to the ciliary
axoneme, many PCD variants are associated with male
infertility. By contrast, it is yet unclear to what extent
women with PCD are affected by subfertility due to
dysfunction of cilia in the fallopian tubes.
Nasal nitric oxide
Measuring nasal nitric oxide (nNO) is a very robust screen-
ing test for PCD as values are very low in most PCD
patients [19-21]. nNO is analyzed by placing a nasal olive
probe into one nostril with a tube connecting the olive
with the analyzer. The measurement is done while the pa-
tient performs an exhalation against resistance manoeuver
in order to close the soft palate and thereby separate
the sinonasal compartment from the bronchial airflow.
Among several commercially available NO analyzers,
most data on reliability and validity exist with chemilu-
miniscence analysers. Using such a device, a nNO pro-
duction rate less than 77 nL/min has a sensitivity and
specificity of 0.98 and >0.999, respectively, for PCD diagno-
sis [20]. As breathing manoeuvers are difficult particularly
for young children, simpler tests such as tidal breathing
sampling are currently evaluated [22,23]. nNO should not
be used as single diagnostic test because low levels can also
be present in cystic fibrosis (CF), sinusitis, nasal polyposis,
and acute upper airways infections and because normal
nNO levels rarely have been reported in PCD patients [21].
High-speed video microscopy
High-speed video microscopy (HVMA) of ciliary beat pat-
tern and frequency of respiratory epithelial cells obtained
by trans-nasal brushing currently is the first-line diag-
nostic test in many centers. Cilia can be observed atD diagnosis
er disorders, for example, acute sinusitis or cystic fibrosis; rarely normal
PCD
g abnormality may be interpreted as normal; secondary ciliary dyskinesia
mation is very common - distinction from PCD phenotype may be difficult
CD cases have no ultrastructural abnormality; false-positive diagnoses
s (notably inner dynein arm defects)
imately ~20%; technical difficulties if specimen contains a lot of mucus
mber of PCD genes; only approximately 60% of cases can be identified
ent
Figure 1 Methods used for PCD diagnosis. (A, B) Immunofluorescence co-staining of human respiratory epithelial cells with DNAH5-specific
antibodies (red) and antibodies against acetylated α-tubulin (green). Nuclei were stained with Hoechst 33342 (blue). Overlays and bright-field images
are shown on the right. Whereas in healthy human respiratory epithelial cells (wt, A) both DNAH5 and acetylated α-tubulin antibodies co-localize along
the entire length of the ciliary axonemes, in an individual with an outer dynein arm defect (B), the ODA heavy chain DNAH5 is absent from the
axonemes. (C) Transmission electron tomography of healthy respiratory epithelial cells (wt) showing no ultrastructural abnormality. Outer
dynein arms (ODAs) are highlighted with red arrows. In an individual with DNAH5 mutations, ODAs are missing. (D) Diagram of ciliary beat
patterns as deduced from high-speed videomicroscopy. A normal ciliary beat pattern (wt) is characterized by a strong beating stroke (symbolized in
grey) followed by a recovery stroke (symbolized in green). In DNAH5 mutant cilia, only a minimal residual ciliary activity is present.
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[24]. HVMA is performed directly after obtaining the spe-
cimen and immediately yields a definite diagnosis in a sub-
set of cases. Ciliary beat abnormalities include static cilia,
almost static cilia with minimal movements, stiff beating
due to a reduced bending capacity/amplitude, abnormal
circular beating and hyperkinetic cilia. These patterns are
linked with specific ultrastructural defects and genetic
variants [24]. Thus, HVMA findings can guide subsequent
analyses revealing the underlying molecular defect. HVMA
though is a challenging method for various reasons: (1)
HVMA protocols differ among centers in many aspects:
sampling techniques, microscopes and cameras, temperature
during analysis, software, and evaluation criteria [24];
(2) Whereas ciliary beat frequencies can be determined
easily, development of objective methods to reliably distin-
guish PCD-specific ciliary beat pattern abnormalities
from normal findings or secondary damage are at a very
provisional stage [25]. Thus, HVMA evaluation remains
strongly dependent on the experience of the investigator;
(3) Recent molecular findings have revealed PCD variants
that may easily be misinterpreted as normal [26,27] ordifficult to assess due to lack of ciliated tissue caused by
defects of multiple motile cilia generation [3,4]; (4) Acute
or chronic infection and inflammation - very common
both in PCD and non-PCD individuals - lead to secondary
ciliary dyskinesia that may be difficult to distinguish from
primary ciliary dyskinesia [2,28]. To overcome diagnostic
difficulties related to secondary abnormalities caused by
infection and inflammation, HVMA as well as transmis-
sion electron microscopy (TEM; see below) or immuno-
fluorescence analysis (IF; see below) can be performed
additionally after in vitro ciliogenesis in respiratory epithe-
lial cell cultures. Although the ciliary beating phenotype
may be altered after cell culture, primary abnormalities are
still present [29,30].
Assessment of ciliary composition by transmission electron
microscopy or immunofluorescence analysis
Analysis of ciliary cross-sections by TEM has been used
traditionally to confirm a PCD diagnosis. However, as this
approach cannot be used to identify an increasing number
of PCD variants (at least 30%; [31,32]) with (near) normal
ultrastructure, this approach can no longer be the ‘gold
A B
C D
Figure 2 Clinical features of primary ciliary dyskinesia. (A) Coronal computed tomography (CT) scan of a 17-year-old PCD individual showing
diffuse pansinusitis with mucosal thickening and polyposis. (B) Endoscopic view showing nasal polyp (same patient). (C) Chest X-ray of a 6-year-
old PCD individual with middle lobe atelectasis. Silhouetting of the right heart border is present. (D) Chest CT of a 6-year-old individual with situs
inversus totalis. The left-sided middle lobe shows extensive bronchiectasis with volume loss (white arrow). In addition, consolidations and mucous
impaction are present in the right upper lobe.
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fied by TEM include a complete or partial absence of
outer dynein arms (ODAs; Figure 1), combined ODA
and inner dynein arm (IDA) defects, and microtubular
disorganization defects. Isolated IDA defects should not
be diagnosed by a single TEM analysis alone as false-
positive diagnoses commonly occur with isolated IDA
defects [33]. Only a subset of radial spoke defects can
be diagnosed by TEM analyses [34]. Defects of nexin
link components [26,35], central pair components [27],
ciliary biogenesis defects [3,4] and defects caused by
DNAH11 mutations [31,36] usually cannot be identified
by routine TEM analysis.
During the last decade, high resolution IF has been in-
troduced as an additional tool to investigate the subcellu-
lar localization of the ciliary proteins in human respiratory
epithelia [37]. Meanwhile, it is possible to reliably identify
all ultrastructural abnormalities detectable by TEM, such
as outer dynein arm defects (Figure 1) or microtubular
disorganization with IDA defect [37-39], and additionally
abnormalities of nexin links components [26] and radial
spoke head proteins [40,41]. The technology has been
adopted by several laboratories and it is likely that further
development will allow recognizing an increasing number
of PCD variants.Genetics
PCD is an autosomal recessive disorder. Mutations in a
rapidly expanding number (currently 31) of genes are
disease-causing (Table 3). The majority of mutations are
loss-of-function variants, while missense mutations can
be found in a minority of cases. Most mutations are pri-
vate. Clustering of mutations in specific genetic regions is
less common than in other genetic disorders. The specific
gene mutations correlate to their structural and video
microscopic phenotype.
Only preliminary evidence correlates genetic findings
with distinct clinical phenotypes. Mutations affecting the
composure of the central pair (HYDIN [27]) or radial
spokes (RSPH1 [34,40], RSPH4A, RSPH9 [59]) as well as
the generation of multiple motile cilia (MCIDAS [3],
CCNO [4]) do not result in situs abnormalities. Patients
with mutations in RSPH1 may have a milder clinical
course [34]. Males with mutations in CCDC114 are not
affected by infertility due to sperm immotility [47]. Sub-
jects with reduced generation of multiple motile cilia
may have a more severe respiratory disease with lung
failure at younger age [3,4].
Modern high-throughput genetic technologies allow
identification of disease-causing biallelic mutations in
approximately ~60% of patients. Although not yet
Table 3 Genes associated with PCD and corresponding ultrastructure
Gene Reference Axonemal/cellular
structure or function
Routine TEM Routine IF



















✓ IDA + ODA defect ✓ ODA component + IDA
component
RSPH1, RSPH4A, RSPH9 [40,59] RSPH subunit (✘) Missing CP or TTD;
often normal
✓ RSPH components
CCDC39, CCDC40 [39,60] NL/DRC factor ✓ microtubular
disorganisation +
IDA-defect
✓ DRC components + IDA
components
CCDC164, CCDC65 [26,58] NL subunit ✘ NL defect only rarely
discernible
✓ NL components
DNAH11 [36] ODA subunit ✘ Normal ✘
HYDIN [27] CP subunit ✘ Normal (C2b absence
only visible in TEM
tomography)
✘












(✘) Usually misinterpreted as
secondary ciliary aplasia;




OFD1, RPGR [61,62] Functions related to
non-motile cilia; role
in motile cilia unknown
✘ Normal/unspecific ✘
aInformative denotes: detectable in routine diagnostics.
CP, central pair tubuli; DRC, dynein regulatory complex; IDA, dynein arm; IF, immunofluorescence microscopy; MMC, multiple motile cilia; NL, nexin link; ODA, outer
dynein arm; RSPH, radial spoke head; TEM, transmission electron microscopy; TTD, tubular transposition defect (8 + 1 structure).
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quencing already is cost-efficient and effective in diagnos-
ing PCD compared to traditional sequential Sanger
sequencing of single genes. However, it has to be kept in
mind that every year novel genetic defects are discovered
and therefore genetic testing cannot be used to rule out a
PCD diagnosis. In addition, expertise is necessary to dis-
tinguish mutations from rare polymorphisms.
Establishing a PCD diagnosis
Given the heterogeneity of possible findings associated
with PCD, there is no uniform approach in diagnosing
PCD. Currently, we consider a PCD diagnosis confirmed
if the following diagnostic criteria are fulfilled: (1) clinical
presentation consistent with PCD; and (2) confirmation of
the diagnosis by at least two of the following methods:
unequivocally abnormal HVMA finding, unequivocally
abnormal TEM finding, unequivocally abnormal IF finding,
abnormally low nNO concentration/production anddemonstration of unequivocal biallelic disease-causing mu-
tations by genotyping. In cases where only HVMA and
nNO concentration/production are abnormal, HVMA
should be repeated at least three times and show the same
abnormal results each time. Individuals with typical clinical
symptoms and only one abnormal diagnostic test are
usually considered to have a possible PCD diagnosis
with exceptions made on an individual basis (for ex-
ample, identification of the same biallelic disease-
causing mutations in a subject of a sibling with a
confirmed diagnosis).
Of note, this approach is provisional, as it is very likely
that further research will continue to modify our under-
standing of different PCD phenotypes.
Management
There is a lack of evidence-based management guidelines
for PCD. Randomized controlled trials have not yet been
performed in this condition. Thus, therapies are deduced
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notably CF and non-CF bronchiectasis. The PCD task
force of the European Respiratory Society has issued rec-
ommendations for the management of PCD highlighting
the importance of routine airway clearance techniques, the
use of antibiotics to control infection, and the avoidance of
harmful agents such as active and passive smoke [11].
To overcome limitations in PCD care, European and
North American investigators and clinicians, as well as pa-
tient support groups, have joined forces in BESTCILIA, a
European Commission funded consortium dedicated to im-
prove PCD care and knowledge (http://www.bestcilia.eu/).
Core programs of this network include: (1) A cross-
sectional observational trial for answering pertinent
questions on clinical phenotype, severity, prognosis, and
effect of treatments on outcomes; (2) An international
prospective PCD registry for systematic data collection
on incidence, clinical presentation, treatments, and course
of the disease. This will allow to monitor trends in man-
agement and outcomes and to recruit patients for trials.
(3) The introduction of standardized diagnostic testing
for PCD in three European countries (Greece, Poland,
Cyprus), where this is currently not available. This ap-
proach will be paradigmatic for other countries how to
implement sophisticated diagnostic facilities; (4) The de-
velopment of PCD-specific health-related quality of life
questionnaires (QoL-PCD) as an outcome measure in
clinical trials. QoL-PCD is furthermore particularly use-
ful to track changes over time and therefore to assess
changes in disease impact on daily life. Therefore, QoL-
PCD will be integrated into the longitudinal international
PCD registry; (5) The first randomized controlled clinical
trial ever performed in PCD to analyze the efficacy and
safety of long-term use of azithromycin.
Monitoring
Ideally, individuals with PCD should be followed up in
specialized centers every 3 months for spirometry, micro-
biological studies of both upper and lower airways secre-
tions, and review of respiratory therapy techniques.
Spirometry is easy to perform, but it is an insensitive
marker of lung function decline, particularly in younger
patients. Therefore, assessment of disease severity using
high-resolution computed tomography (HRCT) should
be considered at larger intervals [63]. Magnetic resonance
imaging (MRI) protocols have been developed showing
good agreement with HRCT for determining extent and
severity of lung disease in non-CF bronchiectasis [64].
Although inferior to HRCT with regard to speed, image
contrast and spatial resolution, MRI is an excellent
radiation-free tool especially for longitudinal analyses.
Possibly, determination of lung clearance index (LCI)
using multiple breath washout may evolve as a tool to
monitor PCD lung disease accurately and non-invasively.It correlates well with HRCT findings in CF and is more
sensitive to early changes in lung physiology. However, a
recent study has failed to demonstrate a correlation be-
tween LCI and HRCT scores in PCD [65].
Monitoring of upper airways disease includes regular
hearing tests that should be performed at least every
6 months in young children and every year in adults.
PCD individuals are at an increased risk to develop sleep
disordered breathing, particularly due to obstructive sleep
apnea syndrome [66,67]. Even if there are currently no
evidence-based data on choice and efficacy of possible
treatment modalities, assessment of sleep disorders should
be part of a PCD management plan.
Lower airways management
Daily airway clearance and aggressive antibiotic treatment
of respiratory tract infections are treatment cornerstones
of PCD lung disease. Review of individualized, age-
appropriate airway clearance therapies should be part
of the regular follow-up visits. No individual technique
has proven superior. Although of unproven benefit, inhal-
ation of hypertonic saline to improve cough clearance is
widely used as is use of bronchodilators. Physical exercise ef-
fectuates general health improvements and therefore is en-
couraged. The role of inhaled rhDNase, a medication
commonly used in CF, is unclear. In non CF-bronchiectasis,
rhDNase has been shown ineffective and therefore it is not
regularly used in PCD [68]. Consistent with this approach,
PCD patients usually do not report changes in sputum
viscosity after rhDNase inhalation. Individuals with PCD
and clear evidence of coexisting asthma can be treated
with inhaled corticosteroids. Otherwise, inhaled cortico-
steroids should be avoided as they might bear the risk of
an increased susceptibility to infections.
Antibiotic treatment of respiratory tract infections
should be instituted promptly and adjusted to micro-
biological findings. Fever is not a reliable symptom in
many PCD individuals. We recommend antibiotics if pa-
tients note an increase in sputum quantity or a change in
sputum viscosity or color. The most commonly cultured
pathogens are Haemophilus influenzae, Staphylococcus
aureus, Moraxella catarrhalis, and Streptococcus pneumo-
niae [69]. Chronic Pseudomonas aeruginosa is found par-
ticularly in adults with advanced disease. It is unclear, if
chronic Pseudomonas aeruginosa infection has similar
detrimental effects on lung function in PCD as in CF.
However, as prompt eradication of potentially harmful
bacteria remains a core goal in PCD management, pro-
tocols based on those used in CF are recommended.
Chronic Pseudomonas aeruginosa infection is often treated
with nebulized antibiotics. Some centers advocate the use
of long-term prophylactic antibiotics. Currently, there is no
evidence for this approach. Empirical knowledge, however,
supports long-term antibiotic use in children requiring
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trial is recruiting patients to test the effects of long-term
Azithromycin use.
Lung surgery in PCD is usually not recommended; in
selected cases of localized disease refractory to conserva-
tive management, lobectomy can be considered. Bilateral
lung transplantation is a treatment option for end-stage
lung failure.
Upper airways management
Impaired mucociliary clearance in the upper airways
affects the nasal cavity, the paranasal sinuses, and the
middle ear. Persistent nasal discharge and blockage is
treated by nasal irrigation. Chronic rhinosinusitis may be
treated additionally by sinonasal inhalation of hypertonic
saline solution and, when infective exacerbations occur,
with antibiotics. Sinus surgery for nasal polyposis bears a
high risk of early recurrence and is therefore performed
only in cases of severely blocked passages. Similar to the
treatment of lower airways disease, topical corticosteroids
are useful only in individuals with additional allergic rhi-
nosinusitis. The role of ventilation tubes for treatment of
conductive hearing loss due to chronic otitis media with
effusion is controversial. Due to the impaired mucociliary
clearance, PCD patients have a higher risk of developing
chronic mucopurulent discharge after ventilation tube
insertion [11,70]. Therefore, hearing aids are preferred
to manage hearing loss. By contrast, a recent report suggests
that hearing may be improved by ventilation tubes, and
otorrhea can be controlled [71]. These controversial reports
highlight the lack of evidence based medical approaches.
Non-respiratory manifestations
Congenital heart disease, when present, usually requires
corrective or palliative surgery. Male or female infertility
is managed with adequate reproductive techniques. How-
ever, as men with PCD are not always infertile and women
only have a slightly decreased fertility (if at all), birth con-
trol measures are necessary if there is no wish to have
children.
Conclusions
Many PCD individuals receive suboptimal management
because there are no evidence-based treatment guide-
lines. Establishing the diagnosis requires several comple-
mentary tests. A multidisciplinary management approach
is well recognized to benefit long-term outcomes. Regular
surveillance should include lung function testing, micro-
biological studies, and review of airway clearing tech-
niques. Currently, management is mainly deduced from
evidence from other suppurative lung diseases.
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